The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations ...

Nivolumab (Opdivo), when given alone or in combination with ipilimumab (Yervoy), led to significant benefit in 10-year ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding ...

Oncology nurses at local and specialized centers can work together to create a pathway for patients throughout CAR T-cell ...

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...